SCHEDULE: FMR LLC Discloses Jazz Pharmaceuticals Stake

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 7.4% of Jazz Pharmaceuticals PLC's common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Jazz Pharmaceuticals PLC common stock.
• As of June 30, 2026, the total number of shares beneficially owned is 4,675,458.82.
• This represents 7.4% of the class of securities.
• FMR LLC has sole voting power for 4,618,210.03 shares and sole dispositive power for 4,675,458.82 shares.
• Abigail P. Johnson has sole dispositive power for 4,675,458.82 shares.
• The filing is made by FMR LLC, a Delaware entity, and Abigail P. Johnson, a U.S. citizen.
• Several subsidiaries of FMR LLC are listed as investment advisers (IA) or banks (BK), including FIAM LLC, Fidelity Diversifying Solutions LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FIAM (UK) Limited, and Strategic Advisers LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not contain new operational or financial performance information.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant stake, indicating continued confidence or investment strategy in Jazz Pharmaceuticals.
• The filing clearly outlines the beneficial ownership structure and percentages.

Negatives

• No new operational or financial performance data is provided in this filing, limiting insights into the company's current health.

Risks

• The filing does not explicitly mention any new risks associated with the investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Jazz Pharmaceuticals PLC's future performance.

Management Comments

• Stephanie J. Brown, Duly authorized under Power of Attorney, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors and investment management firms like FMR LLC when their beneficial ownership of a public company's stock crosses a certain threshold. This filing indicates FMR LLC's ongoing investment in the pharmaceutical sector, specifically in Jazz Pharmaceuticals.

Related Party Transactions

• The filing notes that members of the Johnson family, including Abigail P. Johnson, are predominant owners of FMR LLC's voting shares and have entered into a shareholders' voting agreement.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding significant ownership, which can influence market perception and trading activity.
• Management: The filing confirms the substantial investment by a major financial institution, potentially signaling confidence or a long-term investment horizon.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any material changes in their beneficial ownership of Jazz Pharmaceuticals PLC stock as required by SEC regulations.

Key Dates

Keywords

Jazz Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Investment Adviser, Fidelity